Abstract: Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.

Abstract: An additively manufactured article is assembled from a plurality of printed voxels. The article includes a lattice of unit cells of a composite lattice material and an encasing matrix of structural material arranged between adjacent unit cells of the lattice. The structural material has greater mechanical strength than the composite lattice material.

Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.

Abstract: A reflector unit may behave as a retroreflector to reflect light of a selected color. The reflector unit may comprise a first reflector having a first color, a second reflector having a second color, and a mask that either allows incoming light to reach the first reflector and not the second reflector or allows incoming light to reach the second reflector and not the first reflector. An active light unit may emit light of a particular color in response to receiving light. In this fashion, the active light unit may simulate the operation of a reflector. The reflector unit and the active light unit may operate on a bi-directional vehicle.

Abstract: Techniques are disclosed for acquiring MR signals of an object under examination in an MR system using a multi echo imaging sequence. The method comprises the steps of applying an RF excitation pulse to the object to generate a transverse magnetization, applying at least two RF refocusing pulses for refocusing the transverse magnetization to generate at least two MR spin echoes for the RF excitation pulse, applying a first magnetic field gradient in a read out direction between the RF excitation pulse and the first of the at least two RF refocusing pulses, applying a second magnetic field gradient in the read out direction after each of the at least two RF refocusing pulses such that the zeroth and first gradient moment is substantially zero for the second magnetic field gradient, and acquiring the at least two MR spin echoes during the at least two second magnetic field gradients.

Abstract: Examples are disclosed that relate to computing device input systems. In one example, a computing device input system comprises an input configured to receive a connection to a control device connector comprising a plurality of conductors. The computing device input system further comprises circuitry configured to determine a presence, type, and state of a control device in communication with the control device connector based on analog voltages received from the control device connector.

Abstract: A method of manufacturing a 3-dimensional variable refractive-index optical-element with surface figure, the method comprising: depositing a plurality of nanocomposite-inks comprising an organic-matrix with a nanoparticle filler dispersed within, and at least partially curing a portion of the nanocomposite-ink to form a nanocomposite slab that is at least semi-solid; transferring the nanocomposite slab to a press, the press having a die mold with at least a first surface figure; and actuating the press to compress the nanocomposite slab and impart the die mold's first surface figure onto the nanocomposite slab to form a nanocomposite optical-element.

Abstract: A coating composition includes: (a) a phosphorus acid functional polyol polymer having an acid value within a range of greater than 7 mg KOH/g and 33 mg KOH/g or less, and a hydroxyl value within a range of from 60 to 200 mg KOH/g; (b) an aminoplast derived crosslinker reactive with the phosphorus acid functional polyol polymer; and (c) a non-aqueous liquid medium. Further, if an external catalyst is present, the coating composition comprises less than 0.25 weight % of the external catalyst based on the total weight of the coating composition. The coating composition cures at a temperature of 100° C. or less.

Abstract: An apparatus with integrated optical waveguides. The apparatus has: a plurality of layers, wherein a conductive pathway is patterned on a surface of at least one of the plurality of layers. The plurality of layers are laminated together. A plurality of nanocomposite-inks, each with a nanofiller dispersed in an organic matrix have optical dispersion different from the other plurality of nanocomposite-ink, form the optical waveguides. The optical waveguides are formed on the surface of, or within, at least one of the plurality of layers.

Abstract: The use of chlorine dioxide (CLO2) to kill or disable pathogens such as viruses, particularly those of the Coronavirus family. A certain amount of CLO2 is used via different modalities, particularly through one's nose or mouth, as a therapeutic. CLO2 can treat, cure and/or prevent diseases, such as methicillin resistant Staphylococcus aureus (MRSA), fungal infections, the common cold, and more particularly a current disease in the year 2020, known as COVID-19. The invention will not only kill or disable SARS CoV-2, which causes COVID-19, but will also kill or disable the next Coronavirus, SARS CoV-3, once CoV-2 mutates and escapes any vaccine against it.

Abstract: A method of manufacturing a nanocomposite GRIN optical-element. The method comprises providing a volumetric gradient refractive profile and providing a plurality of nanocomposite-inks to form the GRIN optical-element. Each of the plurality of nanocomposite-inks have nanoparticles dispersed in an organic-matrix. The plurality of nanocomposite-inks comprising of a nanoparticle diffusion inhibiting nanocomposite-ink wherein nanoparticle diffusion is inhibited with respect to another of the plurality of nanocomposite-inks. The diffusion inhibiting nanocomposite-ink having a different dielectric property from at least one of the other plurality of nanocomposite-inks. The plurality of nanocomposite-inks also comprising a nanoparticle diffusion permitting nanocomposite-ink wherein nanoparticle diffusion is permitted with respect to at least another of the plurality of nanocomposite-inks.

Abstract: The invention provides compositions containing cargo molecules attached to elements that improve the function of the cargo molecules in the body of a subject. The compositions are useful for therapeutic and diagnostic purposes. Furthermore, the invention outlines ways in which these compositions can be produced; the core molecule can be functionalized, via bioorthogonal click chemistry, in such a way as to impart modular characteristics. This functionalization simultaneously allows for loading of biologically relevant cargo and provides stabilization to the overall structure of the molecule.

Abstract: A hydrogen peroxide sterilization device for sterilizing a medical device, the hydrogen peroxide sterilization device including a hermetic outer container, a hydrogen peroxide pouch, and a hydrogen peroxide solution in the solution chamber. The hermetic outer container includes a sterilization enclosure configured to receive the medical device. The hydrogen peroxide pouch includes a permeable membrane enclosing a solution chamber and is configured to be positioned in the sterilization enclosure of the outer container. The permeable membrane is configured to allow hydrogen peroxide vapor to diffuse from the solution chamber through the permeable membrane into the sterilization enclosure.

Abstract: In various applications, the system provides a method for processing audio signals, including: receiving a request for audio content; receiving an identifier encoded in a personal audio device comprising a transducer for playing audio; retrieving at least one parameter associated with the identifier; and processing the audio content using at least the request, the identifier and the at least one parameter, wherein the processing is customized for the personal audio device based on the at least one parameter associated with the identifier.

Abstract: Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof.

Abstract: A wireless access point serves dynamic direction-of-arrival reception. An access point radio wirelessly receives a wireless signal that transports time-domain data. Access point circuitry determines uplink utilization for the access point radio. The circuitry transforms the time-domain data into frequency-domain data. The circuitry filters the frequency-domain data for one direction-of-arrival responsive to the uplink utilization. The circuitry synthesizes the time-domain data from the filtered frequency-domain data. The radio wirelessly receives another wireless signal that transports additional time-domain data. The circuitry determines a higher uplink utilization for the access point radio. The circuitry transforms the additional time-domain data into additional frequency-domain data. The circuitry filters the additional frequency-domain data for multiple directions-of-arrival responsive to the higher uplink utilization.

Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g.

Abstract: Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.

Abstract: The invention provides compositions for delivery of cargo to cells. The invention also provides compositions that bind multiple agents simultaneously. The compositions are useful as therapeutics. Methods of using the compositions are also provided.

Abstract: A method includes determining a position of a local coil, a coil position, and a position of a body part of a patient, a body part position. Spacing between the coil position and the body part position is determined. An optimized MR sequence is determined. Based on the determined spacing between the coil position and the body part position, it is checked that in a subsequent MR examination of the patient, a predetermined loading threshold value (e.g., an SAR value) is not exceeded. The optimization of the MR sequence thus takes place under the boundary condition that the loading threshold value is not exceeded.